📰 Efficacy Analysis News
Efficacy Analysis News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Efficacy Analysis. Real-time updates on events, politics, business and more.
November 29, 2023
Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker...
November 29, 2023
Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker…
October 19, 2023
Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 -- Pliant Therapeutics, Inc. , a clinical-stage...
April 17, 2023
Data suggest Cyclin E1 plays a critical role in high proportion of multiple tumor types including platinum-resistant ovarian cancer Company anticipates sharing clinical data from ovarian chemotherapy... | April 17, 2023
December 5, 2022
05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...
November 22, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...
November 22, 2022
/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 65 company and partner abstracts across 8 types of cancer during the upcoming American...
November 3, 2022
- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib
June 24, 2022
Gilead to Present Latest Data From Across Liver Disease Development Programs at the International Liver Congress™ 2022
October 23, 2021
Early Clinical Activity and Safety Profile Support Continued Investigation of Repotrectinib in Pediatric Tumors Harboring ALK, ROS1 or NTRK Alterations ...